Journal of Cancer Immunology & Therapy

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +44-7360-538437

About The Journal Open Access

Journal of Cancer Immunology & Therapy

The journal welcomes submissions from all related fields to the Cancer Immunology & Therapy which utilises the immune system as a treatment for cancer. Cancer immunology is an interdisciplinary branch of biology that is concerned with understanding the role of the immune system in the progression and development of cancer; the most well-known application is cancer immunotherapy.

Aims and Scope

Journal of Cancer Immunology & Therapy is a peer-reviewed, open access journal that reflects articles on all types of tumor immunology. The journal serves as a forum for new concepts and advances in basic Cancer Discovery, Cancer Epidemiology, Biomarkers & Prevention, Cancer Immunology Research, Cancer Surgery, Advances in Cancer Prevention, Breast Cancer, Cancer Biology, Cancer Treatment, Cancer Management and Research, Integrative Cancer Therapies, Clinical cancer immunology and therapy.

Journal of Cancer Immunology & Therapy organize a new platform for the researchers, scientists, scholars, students in this field to publish their research work & update the latest research information to the scientific community. Chief criteria for acceptance are scientific novelty and quality, originality, clarity, and conciseness with early online publication, regular podcasts and an immense archive collection.

You can submit your manuscript at https://www.scholarscentral.org/submissions/cancer-immunology-therapy.html as an email attachment to the e-mail id at [email protected]

Fast Editorial Execution and Review Process (FEE-Review Process):

The Journal of Cancer Immunology and Therapy is participating in the Fast Editorial Execution and Review Process (FEE-Review Process) with an additional prepayment of $99 apart from the regular article processing fee. Fast Editorial Execution and Review Process is a special service for the article that enables it to get a faster response in the pre-review stage from the handling editor as well as a review from the reviewer. An author can get a faster response of pre-review maximum in 3 days since submission, and a review process by the reviewer maximum in 5 days, followed by revision/publication in 2 days. If the article gets notified for revision by the handling editor, then it will take another 5 days for external review by the previous reviewer or alternative reviewer.

Acceptance of manuscripts is driven entirely by handling editorial team considerations and independent peer-review, ensuring the highest standards are maintained no matter the route to regular peer-reviewed publication or a fast editorial review process. The handling editor and the article contributor are responsible for adhering to scientific standards. The article FEE-Review process of $99 will not be refunded even if the article is rejected or withdrawn for publication.

The corresponding author or institution/organization is responsible for making the manuscript FEE-Review Process payment. The additional FEE-Review Process payment covers the fast review processing and quick editorial decisions, and regular article publication covers the preparation in various formats for online publication, securing full-text inclusion in a number of permanent archives like HTML, XML, and PDF, and feeding to different indexing agencies.

H-index

Articles published in Journal of Cancer Immunology & Therapy have been cited by esteemed scholars and scientists all around the world. Journal of Cancer Immunology & Therapy has got H-index 2 , which means every article in Journal of Cancer Immunology & Therapy has got 2 average citations.

Please submit your manuscript to
[email protected]

Just Published Articles View More

Perspective October 04, 2022

P.1-2

J Cancer Immunol Ther: 5(4): 1-2

Different types of endometrial cancer in current times.

Raffone Lucy*

DOI:

Opinion Article October 04, 2022

P.1-2

J Cancer Immunol Ther: 5(4): 1-2

An insight about synovial carcinoma and its treatment in current times.

Sambri Pirni*

DOI:

Commentary October 04, 2022

P.1-2

J Cancer Immunol Ther: 5(4): 1-2

Current treatment strategies for endometrial cancer.

Anne Rice*

DOI:

Mini Review October 04, 2022

P.1-2

J Cancer Immunol Ther: 5(4): 1-2

A detailed research on pathophysiology of ocular carcinoma.

Joseph Conrad*

DOI:

Commentary October 04, 2022

P.1-2

J Cancer Immunol Ther: 5(4): 1-2

Ocular carcinoma its clinical treatment and diagnosis in current times.

Louis Peitzman*

DOI:

Opinion Article June 29, 2022

P.1-2

J Cancer Immunol Ther: 5(3): 1-2

New researches in treating patients with leukemia.

Ann Landers*

DOI:

Relevant Topics

Get the App